Consensus CSPC Pharmaceutical Group Limited

Stocks

1093

HK1093012172

Pharmaceuticals

Market Closed - Hong Kong S.E. 03:08:17 2026-11-13 am EST			5-day change	1st Jan Change
8.030 ^HKD	-4.35%		-4.97%	-4.74%

Nov. 06	CSPC Pharma Begins Trial of Pulmonary Fibrosis Drug in China	MT
Nov. 06	CSPC Pharma Begins Trial of B-cell non-Hodgkin Lymphoma Drug in China	MT

Evolution of the Average Target: CSPC Pharmaceutical Group Limited

Evolution of the Target Price: CSPC Pharmaceutical Group Limited

Changes in Analyst Recommendations: CSPC Pharmaceutical Group Limited

a3c4386f4791bd6315c009b.FosllQpDzdekl5lP4h47XzoMERqCMRgZz0E3j-e4anU.RsFt30sSvp3e-us5i1lNNV9pV1bNY1ROrDUGuo_CDERFvVesYgWav-b-yA~e969f9ad866d9ff0f2f9e8bc1b169ac1

Analysts' recommendations: CSPC Pharmaceutical Group Limited

Aug. 24	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy	MT
Aug. 21	UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50	MT
Jul. 27	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.31 From HK$12.04, Keeps at Buy	MT
May. 28	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Sell from Hold; Price Target is HK$6	MT
Mar. 26	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.20 From HK$5.90, Keeps at Underperform	MT
Feb. 16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy	MT
Nov. 21	UOB Kay Hian Downgrades CSPC Pharmaceutical Group to Hold from Buy; Price Target is HK$8.50	MT
Nov. 21	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$9.11 from HK$10.09, Keeps at Buy	MT
25-10-19	CSPC Pharmaceutical says JSKN003 granted breakthrough therapy designation in China	RE
25-10-13	CSPC Pharmaceutical announces NMPA acceptance of new drug application for Efmedaglutide Alfa Injection	RE
25-10-09	CSPC Pharmaceutical's Hypertriglyceridemia Drug Secures FDA Nod for US Trial	MT
25-08-25	Jefferies Adjusts CSPC Pharmaceutical Group's Price Target to HK$5.90 From HK$5, Keeps at Underperform	MT
25-07-17	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.09 From HK$10.22, Keeps at Buy	MT
25-07-16	Macquarie Upgrades CSPC Pharmaceutical Group to Outperform from Neutral; Price Target is HK$10.30	MT
25-06-16	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.22 From HK$8.02, Keeps at Buy	MT
25-05-29	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.02 From HK$6.55, Keeps at Buy	MT
25-03-31	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.55 From HK$6.48, Keeps at Buy	MT
25-02-26	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$6.48 From HK$7.02, Keeps at Buy	MT
24-11-18	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$7.02 From HK$8.46, Keeps at Buy	MT
24-10-22	Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$8.46 From HK$9.29, Keeps at Buy	MT
24-08-23	Zhongtai International Downgrades CSPC Pharmaceutical to Neutral From Buy; Price Target is HK$6.10	MT
24-08-22	Nomura Adjusts CSPC Pharmaceutical's Price Target to HK$9.29 From HK$9.83, Keeps at Buy	MT
24-08-22	Daiwa Securities Downgrades CSPC Pharmaceutical to Neutral From Outperform; Price Target is HK$6	MT
24-08-22	UOB Kay Hian Downgrades CSPC Pharmaceutical to Sell From Buy; Price Target is HK$5	MT
24-08-22	Bank of China International Downgrades CSPC Pharmaceutical to Hold From Buy; Price Target is HK$6.50	MT

More recommendations

Other Pharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSPC PHARMACEUTICAL GROUP LIMITED					+50.96%
	ELI LILLY AND COMPANY					+2.31%
	JOHNSON & JOHNSON					-1.45%
	ABBVIE INC.					+5.89%
	ROCHE HOLDING AG					-2.48%
	MERCK & CO., INC.					+9.92%
	NOVARTIS AG					-4.16%
	ASTRAZENECA PLC					+16.9%
	AMGEN INC.					-7.55%
	GILEAD SCIENCES, INC.					+4.06%
	Average					+7.44%
	Weighted average by Cap.					+2.51%